phenethylamine has been researched along with Depressive Disorder, Major in 1 studies
phenethylamine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7016
2-phenylethylamine : A phenylethylamine having the phenyl substituent at the 2-position.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deprenyl/Selegiline (DEP), created by Joseph Knoll in the 1960s, registered in more than 60 countries to treat Parkinson's disease, Alzheimer's disease, major depressive disorder; and used as an anti-aging drug, achieved its place in research and therapy as the first selective inhibitor of B-type monoamine oxidase (MAO-B)." | 4.93 | The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). ( Miklya, I, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miklya, I | 1 |
1 review available for phenethylamine and Depressive Disorder, Major
| Article | Year |
|---|---|
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
Topics: Aging; Alzheimer Disease; Animals; Brain; Catecholamines; Depressive Disorder, Major; Dopamine; Hist | 2016 |